Article Text

Download PDFPDF
Safely restarting GI endoscopy in the era of COVID-19
  1. Bu'Hussain Hayee1,
  2. Mo Thoufeeq2,
  3. Colin J Rees3,
  4. Ian Penman4,
  5. James East5,6
  1. 1 King's Health Partners Institute for Therapeutic Endoscopy, King's College Hospital, London, UK
  2. 2 Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
  3. 3 Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
  4. 4 Centre for Liver and Digestive Disorders, Edinburgh Royal Infirmary, Edinburgh, UK
  5. 5 Translational Gastroenterology Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK
  6. 6 Molecular Diagnostics, NIHR Oxford Biomedical Research Centre, Oxford, UK
  1. Correspondence to Dr Bu'Hussain Hayee, King's Health Partners Institute for Therapeutic Endoscopy, King's College Hospital, London SE5 9RS, UK; b.hayee{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


The COVID-19 pandemic has placed extraordinary demands on healthcare services worldwide. Strategic planning for acute COVID-19 care has, during the peak phase of the pandemic, rightly overshadowed the provision of diagnostic services, which have been further restricted by the need to minimise viral transmission to reduce the attendant risks to patients and staff. The risk is compounded by the asymptomatic phase of COVID-19 infection1 and is particularly important in relation to GI endoscopy, given the aerosol-generating nature of many endoscopic procedures.2–4

The British Society of Gastroenterology released early guidance to assist local teams in prioritising certain indications for GI endoscopy, even during the tight restrictions demanded by the peak phase of the pandemic.2 Other endoscopy societies or expert groups have also published guidance on the management of GI endoscopy during the pandemic, and these are summarised elsewhere.5

In the deceleration phase of the pandemic, as defined by a sustained fall in new infectious cases over 14 consecutive days,6 7 healthcare systems will rightly look to implement measures to safely restart activity. Endoscopy capacity should be restored as far as possible while ensuring mechanisms are in place to reassure and protect patients and staff from avoidable risk.

There is significant risk in continued delay of diagnostic services. For GI endoscopy, this relates to cancers as well as other time-critical conditions such as IBD. While COVID-19 has tragically accounted for over 200 000 reported deaths by the end of April 2020,8 there were around 18 million cases of cancer worldwide in 2018 and 10 million cancer deaths, with colorectal and gastric cancer accounting for 17% of deaths.9 It has been conservatively estimated that delays to cancer diagnoses and treatment could be responsible for nearly 7000 additional deaths in England and over 30 000 deaths in the USA.10 It …

View Full Text


  • Twitter @IBDdoc

  • Contributors All authors contributed to the preparation of this manuscript.

  • Funding JE was funded by the National Institute for Health Research Oxford Biomedical Research Centre.

  • Competing interests JE served on the clinical advisory board for Lumendi and Boston Scientific and the clinical advisory board and ownership for Satisfai Health; and received speaker fees from Falk. CJR received grant funding from ARC Medical, Norgine Pharmaceuticals UK, Olympus Medical UK, 3D Matrix and was an expert witness for ARC Medical. BH received grant funding from Olympus Medical UK, Fujifilm Europe, Takeda Pharmaceuticals UK and AbbVie UK, and served on the clinical advisory board and ownership of Ampersand Health, Surgease Medical Ltd.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement There are no data in this work.